AI assistant
Aurinia Pharmaceuticals Inc. — Director's Dealing 2021
May 12, 2021
31941_dirs_2021-05-12_fa5f8655-a521-4c85-ae33-11722a9c201e.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Aurinia Pharmaceuticals Inc. (AUPH)
CIK: 0001600620
Period of Report: 2021-05-11
Reporting Person: Greenleaf Peter (Director, Chief Executive Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-05-11 | Common Stock | P | 2133 | $10.15 | Acquired | 10461 | Direct |
| 2021-05-11 | Common Stock | P | 2992 | $11.11 | Acquired | 13453 | Direct |
Footnotes
F1: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $9.74 to $10.64, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
F2: The price in column 4 is a weighted average price. These shares were purchased in multiple transactions ranging from $10.91 to $11.275, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.